MAINTAINING J&J'S MOMENTUM - CEO William Weldon has a daunting challenge: Keeping the Johnson & Johnson juggernaut on course. For the past two decades, the health-care company posted double-digit earnings growth without fail. But with sales of (USD)36 billion, the once-reliable method of snapping up other companies barely budges the bottom line. And most or J&J's drugs are under competitive ...
Year of publication:
Business week : BW. - New York, NY : McGraw-Hill, ISSN 0007-7135, ZDB-ID 2402762. - 2003 (05.05.), p. 40-44